Publications by authors named "Brenda Ngo"
Article Synopsis
- The study was a phase I trial focusing on the safety, pharmacokinetics, and effectiveness of tinengotinib, a multi-kinase inhibitor, in patients with advanced solid tumors.
- Forty-eight patients participated, with a recommended daily dose established at 12 mg; common side effects included hypertension and a specific skin condition.
- Preliminary results showed that tinengotinib was well tolerated and 30.2% of patients experienced clinical benefits, including some with specific types of cancer, suggesting potential effectiveness.
Single nucleotide polymorphisms (SNPs) are exceedingly common in non-coding loci, and while they are significantly associated with a myriad of diseases, their specific impact on cellular dysfunction remains unclear. Here, we show that when exposed to external stressors, the presence of risk SNPs in the 9p21.3 coronary artery disease (CAD) risk locus increases endothelial monolayer and microvessel dysfunction.
View Article and Find Full Text PDF